Efficacy and safety of dacomitinib as first-line treatment for advanced non-small cell lung cancer patients with epidermal growth factor receptor 21L858R mutation:A multicenter, case-series study in China
Chinese Journal of Cancer Research
頁(yè)數(shù)： 12 2024-08-15
摘要： Objective: To provide real-world evidence for the application of first-line dacomitinib treatment for epidermal growth factor receptor(EGFR) 21L858R mutant non-small cell lung cancer(NSCLC) ... （共12頁(yè)）
APP 